Enlivex Therapeutics has completed Phase II enrollment for its trial of Allocetra in knee osteoarthritis, with 133 subjects randomized. Positive interim results from Phase I guided dosage for Phase II, which includes an independent interim assessment and plans to increase patient cohort.